
  
    
      
        
        Acquired_VBN resistance_NN to_TO chemotherapy_NN is_VBZ a_DT major_JJ obstacle_NN to_TO successful_JJ cancer_NN treatment_NN ._.
        Understanding_NNP the_DT mechanisms_NNS by_IN which_WDT tumors_NNS become_VBP resistant_JJ to_TO a_DT particular_JJ agent_NN is_VBZ key_JJ
        to_TO identifying_VBG new_JJ drugs_NNS or_CC combination_NN regimens_NNS ._.
        Kinases_NNP are_VBP signaling_VBG molecules_NNS that_WDT control_NN many_JJ aspects_NNS of_IN cell_NN behavior_NN ,_, including_VBG
        cell_NN proliferation_NN ,_, i_NNP ._. e_SYM ._. ,_, whether_IN and_CC how_WRB fast_RB cells_NNS divide_VBP ._. Abnormally_NNP active_JJ kinases_NNS
        promoting_VBG tumor_NN growth_NN are_VBP found_VBN in_IN many_JJ cancers_NNS and_CC are_VBP a_DT focus_NN of_IN rational_JJ cancer_NN drug_NN
        design_NN ._. One_CD target_NN for_IN kinase_NN inhibitors_NNS is_VBZ the_DT epidermal_NN growth_NN factor_NN receptor_NN (_( EGFR_NNP )_) ._.
        Two_CD EGFR_NNP inhibitors_NNS ,_, gefitinib_NN and_CC erlotinib_NN ,_, showed_VBD therapeutic_JJ benefits_NNS in_IN a_DT subset_NN of_IN
        patients_NNS with_IN non-small_JJ cell_NN lung_NN cancer_NN ._. Recent_JJ work_NN has_VBZ helped_VBN us_PRP understand_VBP why_WRB some_DT
        patients_NNS respond_VBP and_CC some_DT do_VBP n't_RB :_: responsive_JJ tumors_NNS usually_RB harbor_VBP activating_VBG mutations_NNS in_IN
        the_DT EGFR_NNP gene_NN ,_, which_WDT somehow_RB make_VB the_DT tumors_NNS sensitive_JJ to_TO treatment_NN ._. Nearly_RB all_DT patients_NNS
        whose_WP$ tumors_NNS initially_RB respond_VBP to_TO EGFR_NNP inhibitors_NNS ,_, however_RB ,_, eventually_RB become_VB resistant_JJ to_TO
        the_DT drugs_NNS and_CC progress_NN despite_IN continued_JJ therapy_NN ._.
        William_NNP Pao_NNP and_CC colleagues_NNS examined_VBD tumors_NNS from_IN six_CD patients_NNS with_IN non-small_JJ cell_NN lung_NN
        cancer_NN who_WP initially_RB responded_VBD to_TO gefitinib_NN or_CC erlotinib_NN but_CC subsequently_RB relapsed_JJ ._. Tumors_NNP
        from_IN all_DT six_CD patients_NNS carried_VBD activating_VBG mutations_NNS in_IN the_DT EGFR_NNP gene_NN ._. In_IN addition_NN ,_, in_IN three_CD
        out_IN of_IN the_DT six_CD cases_NNS ,_, the_DT resistant_JJ tumor_NN cells_NNS carried_VBD an_DT identical_JJ second_JJ mutation_NN in_IN the_DT
        EGFR_NNP gene_NN ._. Whereas_IN the_DT activating_VBG mutation_NN was_VBD present_JJ in_IN tumor_NN cells_NNS before_IN treatment_NN with_IN
        erlotinib_NN or_CC gefitinib_NN ,_, the_DT second_JJ mutation_NN was_VBD not_RB found_VBN in_IN pre-treatment_JJ biopsies_NNS from_IN
        these_DT patients_NNS ,_, nor_CC in_IN over_IN 150_CD lung_NN cancer_NN samples_NNS from_IN patients_NNS who_WP had_VBD not_RB been_VBN treated_VBN
        with_IN either_DT drug_NN ._. Additional_JJ cell_NN culture_NN studies_NNS supported_VBD the_DT notion_NN that_IN the_DT secondary_JJ
        mutation_NN causes_NNS resistance_NN to_TO gefitinib_NN or_CC erlotinib_NN ._. It_PRP is_VBZ clear_JJ ,_, though_RB ,_, that_IN this_DT is_VBZ
        only_RB one_CD mechanism_NN of_IN resistance_NN ,_, because_IN in_IN the_DT three_CD other_JJ cases_NNS resistance_NN occurred_VBD in_IN
        the_DT absence_NN of_IN the_DT second_JJ mutation_NN ._. What_WP caused_VBD the_DT resistance_NN in_IN those_DT tumors_NNS is_VBZ not_RB
        known_VBN ._.
        All_DT kinases_NNS share_VBP some_DT common_JJ features_NNS ,_, and_CC a_DT resistance_NN mutation_NN very_RB similar_JJ to_TO the_DT
        one_CD identified_VBN here_RB has_VBZ also_RB been_VBN found_VBN in_IN other_JJ kinase_NN genes_NNS from_IN tumors_NNS with_IN acquired_VBN
        resistance_NN to_TO imatinib_NN ,_, another_DT kinase_NN inhibitor_NN ._. As_IN Gary_NNP Gilliland_NNP and_CC colleagues_NNS point_VBP
        out_IN in_IN an_DT accompanying_VBG Perspective_NNP (_( DOI_NNP :_: 10_CD ._. 1371_CD /_NN journal_NN ._. pmed_JJ ._. 0020075_CD )_) ,_, the_DT initial_JJ
        identification_NN three_CD years_NNS ago_RB of_IN resistance_NN mutations_NNS against_IN imatinib_NN led_VBN to_TO the_DT rapid_JJ
        development_NN of_IN alternative_JJ kinase_NN inhibitors_NNS that_WDT work_NN even_RB against_IN tumors_NNS with_IN the_DT
        resistance_NN mutation_NN ._. Similarly_RB ,_, the_DT results_NNS by_IN Pao_NNP and_CC colleagues_NNS should_MD help_VB researchers_NNS
        develop_VB second_JJ generation_NN drugs_NNS for_IN lung_NN cancer_NN ._.
      
    
  
